Cargando…

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls

Inherited germline pathogenic variants are responsible for ~5% of breast cancer globally. Through rapid expansion and isolation since immigration in the early 17(th) century, French Canadians are a relatively genetically homogenous founder population and therefore represent a unique demographic for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Behl, Supriya, Hamel, Nancy, de Ladurantaye, Manon, Lepage, Stéphanie, Lapointe, Réjean, Mes-Masson, Anne-Marie, Foulkes, William D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162921/ https://www.ncbi.nlm.nih.gov/pubmed/32300229 http://dx.doi.org/10.1038/s41598-020-63100-w

Ejemplares similares

Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer
por: Hamel, Nancy, et al.
Publicado: (2003)

Contribution of the PALB2 c.2323C>T [p.Q775X] Founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent
por: Tischkowitz, Marc, et al.
Publicado: (2013)

Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families
por: Oros, Kathleen K, et al.
Publicado: (2006)

Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada
por: Hartley, Taila, et al.
Publicado: (2014)

PALB2 (partner and localizer of BRCA2)
por: Hanenberg, Helmut, et al.
Publicado: (2018)

PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response
por: Simhadri, Srilatha, et al.
Publicado: (2018)

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent
por: Cavallone, Luca, et al.
Publicado: (2008)

Compromised BRCA1-PALB2 interaction is associated with breast cancer risk
por: Foo, Tzeh Keong, et al.
Publicado: (2017)

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals
por: Kuusisto, Kirsi M, et al.
Publicado: (2011)

Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2
por: Hartford, Suzanne A., et al.
Publicado: (2016)

Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development
por: Huo, Yanying, et al.
Publicado: (2021)

Surgery for BRCA, TP53 and PALB2: a literature review
por: Song, Chin-Vern, et al.
Publicado: (2018)

Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families
por: Pylkäs, Katri, et al.
Publicado: (2008)

Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
por: Wojcik, P., et al.
Publicado: (2016)

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population
por: Belanger, Moria H, et al.
Publicado: (2015)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
por: Maksimenko, J., et al.
Publicado: (2018)

Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
por: Takeuchi, Shoko, et al.
Publicado: (2018)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study
por: Zhen, David B., et al.
Publicado: (2014)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era
por: Macedo, Gabriel S., et al.
Publicado: (2019)

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
por: Seeber, Andreas, et al.
Publicado: (2020)

The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in BRCA1/BRCA2/PALB2-Negative Women
por: Larionov, Alexey, et al.
Publicado: (2023)

Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants
por: Alenezi, Wejdan M., et al.
Publicado: (2022)

Identification of a founder BRCA2 mutation in Sardinia
por: Pisano, M, et al.
Publicado: (2000)

Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers
por: Hamid, Abdulaziz B., et al.
Publicado: (2022)

Mutations of BRCA1, BRCA2, and PALB2 Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis
por: Tsyganov, Matvey M., et al.
Publicado: (2023)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women
por: Foulkes, William D, et al.
Publicado: (2007)

Analysis of PALB2 Gene in BRCA1/BRCA2 Negative Spanish Hereditary Breast/Ovarian Cancer Families with Pancreatic Cancer Cases
por: Blanco, Ana, et al.
Publicado: (2013)

Primary Peritoneal Carcinoma in a BRCA1/2-negative, PALB2-positive patient
por: Kahn, Ryan, et al.
Publicado: (2016)

Founder BRCA1 mutations in Nepalese population
por: Mehta, Anurag, et al.
Publicado: (2022)

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families
por: Antoniou, Antonis C, et al.
Publicado: (2006)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
por: Kluz, Tomasz, et al.
Publicado: (2018)

BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina
por: Solano, Angela R., et al.
Publicado: (2018)

Plasticity of BRCA2 Function in Homologous Recombination: Genetic Interactions of the PALB2 and DNA Binding Domains
por: Siaud, Nicolas, et al.
Publicado: (2011)

Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years
por: Petridis, Christos, et al.
Publicado: (2019)

Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation
por: Metcalfe, Kelly A, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_6kdb1erm690lmpnaon0keq1sfp